

Nuclear Radiology

This exam content assesses the candidate's knowledge and skills related to the clinical practice of nuclear radiology. The domain encompasses diagnostic planar, SPECT/CT, and PET/CT imaging using a variety of radiopharmaceuticals. The domain includes oral radioiodine therapy for hyperthyroidism and thyroid cancer.

Included in this document:

[Domain Critical Concepts](#)

[Domain Blueprint](#)

[Domain Overview](#)

Domain Critical Concepts

1. Central Nervous System
 - a. Recognize presence or absence of cerebral blood flow on brain scan
 - b. Differentiate dementias on FDG PET/CT
2. Cardiovascular & Lymphatic Systems
 - a. Distinguish ischemia from scar on myocardial perfusion SPECT
 - b. Understand lymphatic pathways and apply to pre-operative imaging
3. Pulmonary System
 - a. Apply interpretation criteria in diagnosis of acute and chronic pulmonary embolism on V/Q scan
4. Gastrointestinal System
 - a. Recognize and localize active hemorrhage on gastrointestinal bleeding scan
 - b. Differentiate acute and chronic gallbladder disease, and recognize biliary complications on IDA scan
5. Genitourinary System
 - a. Recognize kidney and urinary tract pathology on DMSA and MAG3 scans
6. Musculoskeletal System
 - a. Differentiate benign and malignant skeletal diseases on skeletal scintigraphy
7. Endocrine System
 - a. Localize overactive parathyroid gland(s) on planar and SPECT/CT imaging
8. Infection & Inflammation
 - a. Identify sources of infection and inflammation on planar and SPECT/CT imaging
9. Neoplasms
 - a. Differentiate physiological from pathological biodistribution in oncologic FDG PET/CT
10. Therapy & Theranostics
 - a. Integrate thyroid imaging with uptake and laboratory values to plan radioiodine therapy in hyperthyroidism
 - b. Integrate whole-body imaging with laboratory values and surgical staging to plan radioiodine therapy in thyroid cancer
11. Technical & Quality
 - a. Recognize altered radiopharmaceutical biodistribution
 - b. Recognize imaging artifacts
 - c. Recognize pitfalls in quantitative analysis

Domain Blueprint

1. Central Nervous System (CNS): 8%-9%
2. Cardiovascular & Lymphatic (CV & L) Systems: 8%-9%
3. Pulmonary System: 4%
4. Gastrointestinal (GI) System: 12%-13%
5. Genitourinary (GU) System (including Breast): 8%-9%
6. Musculoskeletal (MSK) System (including Integument): 6%
7. Endocrine System: 6%
8. Infection & Inflammation (I & I): 4%
9. Neoplasms: 25%
10. Therapy & Theranostics: 10%
11. Technical & Quality (excluding Physics & RISE): 6%

Domain Overview

1. Central Nervous System (CNS)
 1. Brain viability
 2. Dementias & behavioral disorders
 3. Movement disorders
 4. Seizure focus
 5. Cerebrovascular disease
 6. Cerebrospinal fluid (CSF)
2. Cardiovascular & Lymphatic (CV & L) Systems
 1. Myocardial perfusion imaging, coronary artery disease
 2. Myocardial perfusion imaging, non-coronary artery disease
 3. Myocardial metabolism & viability
 4. Multigated acquisition (MUGA)/gated cardiac blood pool imaging
3. Pulmonary System
 1. Ventilation & perfusion (thromboembolism; non-thromboembolism; airways)
4. Gastrointestinal (GI) System
 1. Liver & spleen
 2. Biliary
 3. Bowel (GI bleed; GI motility)
5. Genitourinary (GU) System
 1. Renal perfusion & function (native kidneys)
 2. Renal diuretic challenge (native kidneys)
 3. Renal cortex (native kidneys)
 4. Renal transplant
 5. Urinary leak (native & transplant kidneys)
 6. Bladder/nuclear cystogram

6. Musculoskeletal (MSK) System (including Integument)
 1. Tumor-like or associated conditions
 2. Metabolic & vascular conditions
 3. Trauma
 4. Extra-skeletal processes (on skeletal scintigraphy)
7. Endocrine System
 1. Thyroid gland
 2. Parathyroid gland
8. Infection & Inflammation (I & I)
 1. CNS
 2. CV & L
 3. Pulmonary
 4. GI
 5. GU (including Breast)
 6. MSK (including Integument)
9. Neoplasms (benign; malignant primary; malignant metastatic)
 1. CNS
 2. CV & L
 3. Pulmonary
 4. GI
 5. GU (including Breast)
 6. MSK (including Integument)
 7. Endocrine
10. Therapy & Theranostics
 1. GI, parenteral (^{90}Y microspheres: pre-mapping, post-imaging)
 2. Endocrine, oral (^{131}I NaI)
11. Technical & Quality (patient issues/preparation; radiopharmaceutical issues/contamination; imaging issues/protocols/processing/artifacts)
 1. CNS
 2. CV & L
 3. Pulmonary
 4. GI
 5. GU
 6. MSK
 7. Endocrine
 8. I & I
 9. Neoplasms
 10. Therapy & Theranostics